Item 7.01 Regulation FD Disclosure. On January 5, 2021, Inhibrx, Inc. (the "Company") issued a press release announcing results from Part 1 of the Phase 1 dose escalation trial of INBRX-106, a novel hexavalent OX40 agonist, in development for the treatment of solid tumors.

The full text of the Company's press release regarding this announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K. Additionally and as mentioned in the press release, the Company posted an updated copy of its corporate slide presentation to the "Investors" tab of its website at www.inhibrx.com. These slides are also attached to this Current Report on Form 8-K as Exhibit 99.2. The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. It undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.



The information in this Report on Form 8-K, including Exhibits 99.1 and 99.2
attached hereto, is intended to be furnished and shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange
Act") or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933
or the Exchange Act, except as expressly set forth by specific reference in such
filing.
Item 9.01.  Financial Statements and Exhibits.
(d) Exhibits.
 Exhibit No.      Description
99.1                Press Release issued by Inhibrx, Inc. on January 5, 2021
99.2                Corporate presentation

© Edgar Online, source Glimpses